Pillar Biosciences welcomes new independent board member Robert Forrester

Natick, MA, Oct 1, 2020 — Pillar Biosciences, a next-generation sequencing (NGS) clinical cancer diagnostics company, today announced the addition of a new independent board member, Robert Forrester. Mr. Forrester has over two decades of experience in C-level positions in the pharmaceutical industry. Mr. Forrester joins a team of pragmatic experts in diagnostics and oncology dedicated to making precision medicine a practical reality through streamlined NGS workflows.  

Mr. Forrester’s leadership roles in private and public sector pharmaceutical companies include serving as the CEO of Verastem Oncology, COO of Forma Therapeutics, CEO and CFO of CombinatoRx, and CFO of Coley Pharmaceutical. Mr. Forrester is also the co-founder and CXO of EQRx Inc, which is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. Mr. Forrester also served as Managing Director of the Proprietary Investment Group at MeesPierson. He holds a LL.B. from Bristol University. 

Mr. Forrester joins a team of independent advisors that includes Timothy Springer, a Harvard professor in immunology who has been involved in various successful startups such as Moderna Therapeutics; Paul Waring, the Executive Director of Molecular Pathology for AstraZeneca; and Marcia Eisenberg, the CSO and Senior Vice President of LabCorp.  

Robert brings a wealth of industry experience and financial expertise to our growing team of scientific experts,” said Dr. Gang Song, co-founder and CEO of Pillar Biosciences. Additionally, Robert’s work with EQRx demonstrates that he shares our larger vision of making precision medicine accessible to a wide range of molecular diagnostic labs and the patients they serve. 

“What Pillar has developed are truly practical technologies to enable a paradigm shift from send-out testing to in-hospital testing to bring precision medicine closer to the patient,” said Forrester. “I look forward to working with the team to develop what has been an enabling tool for research use into a quicker and cheaper diagnostic solution for patients, providers and payers.”  

Press Contact

William Wright
Director of Sales
info@pillar-biosciences.com

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp®– and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.

Learn more at https://pillar-biosciences.com.

Don’t Stop Here

More To Explore

Pillar Biosciences and PierianDx Announce Partnership to Support Precision Cancer Care

ST. LOUIS & NATICK, Mass., Oct 15, 2020 – PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology …

Read More →

Pillar Biosciences welcomes new independent board member Robert Forrester

Natick, MA, Oct 1, 2020 — Pillar Biosciences, a next-generation sequencing (NGS) clinical cancer diagnostics company, today announced the addition of a new independent board …

Read More →

Pillar Biosciences Closes $29.7 Million in Series C Financing

Financing to Advance IVD and RUO Product Development and to Expand Global Commercialization Natick, MA, May 5, 2020—Pillar Biosciences, an NGS clinical cancer diagnostics company, …

Read More →

New 47-gene solid tumor panel from Pillar Biosciences now available for research use

Pillar Biosciences, the productivity-focused genomics company, today announced that the Pillar® ONCO/Reveal™ Solid Tumor Panel, a 47-gene enrichment assay is now available for research use. …

Read More →

Pillar NGS panels go global with increased platform versatility

Pillar Biosciences, an NGS diagnostics company based in Boston, MA, announced today that Pillar® ONCO/Reveal™ NGS panels are now compatible with Illumina®, Ion Torrent™, and …

Read More →

Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel

BOSTON, May 30, 2019 /PRNewswire/ — Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today that the Columbia Solid Tumor Panel, …

Read More →
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top